Escalating immunotherapy of multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 1, Issue 3, 2008, Pages 181-192

  Rieckmann, Peter ^a   Traboulsee, Anthony ^a   Devonshire, Virginia ^b   Oger, Joel ^b  

^a University of British Columbia ^*

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Clinically isolated syndromes; Glatiramer acetate; Immunotherapy; Interferon beta; Multiple sclerosis; Natalizumab

Indexed keywords

EID: 84993682619     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285608098359     Document Type: Review

References (71)

1. Bar-or, A., Calabresi, P.A., Arnlod, D., Markowitz, C., Shafer, S., Kasper, L.H. et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase i trial, Ann Neurol 63: 395-400.
2. Boster, A., Edan, G., Frohman, E., Javed, A., Stuve, O., Tselis, A. et al. (2008) Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician, Lancet Neurol 7: 173-183.
3. Boz, C., Oger, J., Gibbs, E. and Grossberg, S.E. (2007) Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study, Mult Scler 13: 1127-1137.
4. Buttmann, M. and Rieckmann, P. (2008) Treating multiple sclerosis with monoclonal antibodies, Expert Rev Neurother 8: 433-455.
5. Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group, Lancet 337: 441-446.
6. Carra, A., Onaha, P., Luetic, G., Burgos, M., Crespo, E., Deri, N. et al. (2008) Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina, Eur J Neurol 15: 386-393.
7. Chan, A., Weilbach, F.X., Toyka, K.V. and Gold, R. (2005) Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients, Clin Exp Immunol 139: 152-158.
8. Chen, J.T., Collins, D.L., Atkins, H.L., Freedman, M.S. and Arnold, D.L. (2008) Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions, Ann Neurol 63: 254-262.
9. Chen, J.T., Collins, D.L., Atkins, H.L., Freedman, M.S., Galal, A. and Arnold, D.L. (2006) Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis, Neurology 66: 1935-1937.
10. Cohen, B.A., Khan, O., Jeffery, D.R., Bashir, K., Rizvi, S.A., Fox, E.J. et al. (2004) Identifying and treating patients with suboptimal responses, Neurology 63: S33-S40
11. Cohen, B.A. and Rieckmann, P. (2007) Emerging oral therapies for multiple sclerosis. Int J Clin Pract 61: 1922-1930.
12. Cursiefen, S., Flachenecker, P., Toyka, K.V. and Rieckmann, P. (2000) Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis, Eur Neurol 43: 186-187.
13. Dalton, C., Brex, P., Miszkiel, K., Hickman, S., Macmanus, D., Plant, G. et al. (2002)
14. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis, Ann Neurol 52: 47-53.
15. Donahue, K.E., Gartlehner, G., Jonas, D.E., Lux, L.J., Thieda, P., Jonas, B.L. et al. (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis, Ann Intern Med 148: 124-134.
16. Edan, G., Miller, D., Clanet, M., Confavreux, C., Lyon-Caen, O., Lubetzki, C. et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria, J Neurol Neurosurg Psychiatry 62: 112-118.
17. Farina, C., Weber, M.S., Meinl, E., Wekerle, H. and Hohlfeld, R. (2005) Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action, Lancet Neurol 4: 567-575.
18. Fassas, A. and Kimiskidis, V.K. (2003) Stem cell transplantation for multiple sclerosis: What is the evidence? Blood Rev 17: 233-240.
19. Fauci, A.S., Wolff, S.M. and Johnson, J.S. (1971) Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis, N Engl J Med 285: 1493-1496.
20. Fernandez, O. (2007) Combination therapy in multiple sclerosis, J Neurol Sci 259: 95-103.
21. Flechter, S., Vardi, J., Finkelstein, Y. and Pollak, L. (2007) Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon Beta-1b: An open-label prospective 1 year study. Isr Med Assoc J 9: 457-459.
22. Freedman, M.S., Patry, D.G., Grand'maison, F., Myles, M.L., Paty, D.W. and Selchen, D.H. (2004) Treatment optimization in multiple sclerosis, Can J Neurol Sci 31: 157-168.
23. Gold, R. (2008) Combination therapies in multiple sclerosis, J Neurol 255(Suppl. 1): 51-60.
24. Goodin, D.S., Frohman, E.M., Hurwitz, B., O'Connor, P.W., Oger, J.J., Reder, A.T. et al. (2007) Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Neurology 68: 977-984.
25. Grossberg, S.E., Kawade, Y., Kohase, M. and Klein, J.P. (2001) The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit, J Interferon Cytokine Res 21: 743-755.
26. Hartung, H., Gonsette, R., König, N., Kwiecinski, H., Guseo, A., Morissey, S. et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet 360: 2018-2025.
27. Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J. et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N Engl J Med 358: 676-688.
28. Heesen, C., Kasper, J., Segal, J., Kopke, S. and Muhlhauser, I. (2004) Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis, Mult Scler 10: 643-650.
29. Hohol, M.J., Olek, M.J., Orav, E.J., Stazzone, L., Hafler, D.A., Khoury, S.J. et al. (1999) Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease, Mult Scler 5: 403-409.
30. Hommes, O.R. (1978) [Intensive immunosuppressive treatment of chronic progressive multiple sclerosis], Ned Tijdschr Geneeskd 122: 1545-1551.
31. Jeffery, D.R., Chepuri, N., Durden, D. and Burdette, J. (2005) A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging, Mult Scler 11: 296-301.
32. Jones, J.L. and Coles, A.J. (2008) Campath-1h treatment of multiple sclerosis, Neurodegener Dis 5: 27-31.
33. Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C.H. et al. (2006) Oral fingolimod (Fty720) for relapsing multiple sclerosis, N Engl J Med 355: 1124-1140.
34. Kappos, L., Bates, D., Hartung, H.P., Havrdova, E., Miller, D., Polman, C.H. et al. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring, Lancet Neurol 6: 431-441.
35. Keegan, M., Pineda, A., Mcclelland, R., Darby, C., Rodriguez, M. and Weinshenker, B. (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response, Neurology 58: 143-146.
36. Khan, O.A., Zvartau-Hind, M., Caon, C., Din, M.U., Cochran, M., Lisak, D. et al. (2001) Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy, Mult Scler 7: 185-188.
37. Kieseier, B.C. and Wiendl, H. (2007) Oral disease-modifying treatments for multiple sclerosis: the story so far, CNS Drugs 21: 483-502.
38. Krapf, H., Morrissey, S.P., Zenker, O., Zwingers, T., Gonsette, R. and Hartung, H.P. (2005) Effect of mitoxantrone on MRI in progressive MS: results of the mims trial, Neurology 65: 690-695.
39. Le Page, E., Leray, E., Taurin, G., Coustans, M., Chaperon, J., Morrissey, S.P. et al. (2008) Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients, J Neurol Neurosurg Psychiatry 79: 52-56.
40. Martinelli, V. and Comi, G. (2005) Induction versus escalation therapy, Neurol Sci 26(Suppl. 4): S193-S199
41. McFarland, H.F. (2008) The B cell - old player, new position on the team, N Engl J Med 358: 664-665.
42. Millefiorini, E., Gasperini, C., Pozzilli, C., D'Andrea, F., Bastianello, S., Trojano, M. et al. (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome, J Neurol 244: 153-159.
43. Mstcg (2004) Escalating immunotherapy of multiple sclerosis - new aspects and practical application, J Neurol 251: 1329-1339.
44. Mstcg (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis-current therapeutic recommendations. J Neurol (in press).
45. O'Connor, P. and Devonshire, V. (2008) The use of disease-modifying agents in multiple sclerosis - by the Canadian network of MS clinics, Can J Neurol Sci 35: 127-129.
46. O'Connor, P.W., Li, D., Freedman, M.S., Bar-or, A., Rice, G.P., Confavreux, C. et al. (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses, Neurology 66: 894-900.
47. Phillips, J.T. and Frohman, E.M. (2008) Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 151-153.
48. Pierson, S.H. and Griffith, N. (2006) Treatment of cognitive impairment in multiple sclerosis, Behav Neurol 17: 53-67.
49. Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med 354: 899-910.
50. Polman, C.H., Reingold, S.C., Edan, G., Filippi, M., Hartung, H.P., Kappos, L. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald criteria’, Ann Neurol 58: 840-846.
51. Racke, K. and Stüve, O. (2008) Natalizumab: increased vigilance is required in treating patients with multiple sclerosis, Therapeutic Advances in Neurological Disorders 1: 155-156.
52. Ramtahal, J., Jacob, A., Das, K. and Boggild, M. (2006) Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis, J Neurol 253: 1160-1164.
53. Rieckmann, P., Toyka, K.V., Bassetti, C., Beer, K., Beer, S., Buettner, U. et al. (2004) Escalating immunotherapy of multiple sclerosis - new aspects and practical application, J Neurol 251: 1329-1339.
54. Rio, J., Nos, C., Tintore, M., Tellez, N., Galan, I., Pelayo, R. et al. (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients, Ann Neurol 59: 344-352.
55. Rio, J., Porcel, J., Tellez, N., Sanchez-Betancourt, A., Tintore, M., Arevalo, M.J. et al. (2005) Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis, Mult Scler 11: 306-309.
56. Rose, J.W., Burns, J.B., Bjorklund, J., Klein, J., Watt, H.E. and Carlson, N.G. (2007) Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results, Neurology 69: 785-789.
57. Rothwell, P.M., McDowell, Z., Wong, C.K. and Dorman, P.J. (1997) Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis, BMJ 314: 1580-1583.
58. Rudick, R.A., Lee, J.C., Simon, J., Ransohoff, R.M. and Fisher, E. (2004) Defining interferon beta response status in multiple sclerosis patients, Ann Neurol 56: 548-555.
59. Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N Engl J Med 354: 911-923.
60. Saiz, A., Blanco, Y., Carreras, E., Berenguer, J., Rovira, M., Pujol, T. et al. (2004) Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS, Neurology 62: 282-284.
61. Schrijver, H.M., de Palma, R., Sementa, A., Chaudhuri, A., Behan, P.O., Hauser, S.L. et al. (2008) Rituximab in relapsing-remitting multiple sclerosis, N Engl J Med 358: 2645-2647.
62. Simon, J., Li, D., Traboulsee, A.L., Coyle, P., Arnold, D., Barkhof, F. et al. (2006) Standardized MR imaging protocol for multiple sclerosis: consortium of MS centers consensus guidelines, AJNR Am J Neuroradiol 27: 455-461.
63. Sipe, J.C. (2005) Cladribine for multiple sclerosis: review and current status, Expert Rev Neurother 5: 721-727.
64. Smith, D.R., Weinstock-Guttman, B., Cohen, J.A., Wei, X., Gutmann, C., Bakshi, R. et al. (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta, Mult Scler 11: 573-582.
65. Smolen, J.S., Keystone, E.C., Emery, P., Breedveld, F.C., Betteridge, N., Burmester, G.R. et al. (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis, Ann Rheum Dis 66: 143-150.
66. Sorensen, P.S., Deisenhammer, F., Duda, P., Hohlfeld, R., Myhr, K.M., Palace, J. et al. (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-Beta Antibodies in Multiple Sclerosis, Eur J Neurol 12: 817-827.
67. Stuart, W.H. (2004) Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management, J Manag Care Pharm 10: S19-S25
68. Tyndall, A., Walker, U.A., Cope, A., Dazzi, F., de Bari, C., Fibbe, W. et al. (2007) Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 e October 2005, Arthritis Res Ther 9: 301.
69. Vollmer, T., Panitch, H., Freedman, M., Gasda, S., Bar-or, A., and Arnold, D. (2008) Short-term induction with mitoxantrone preceding treatment with glatiramer acetate offers early and pronounced effects on MRI disease activity in patients with relapsing forms of multiple sclerosis, Multiple Sclerosis (in press).
70. Weiner, H.L., Mackin, G.A., Orav, E.J., Hafler, D.A., Dawson, D.M., Lapierre, Y. et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group, Neurology 43: 910-918.
71. Zephir, H., de Seze, J., Duhamel, A., Debouverie, M., Hautecoeur, P., Lebrun, C. et al. (2004) Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients, J Neurol Sci 218: 73-77.